John M. Reno
48Patents
24h-index
44Co-inventors
85Inventor score
Filing activity: Apr 5, 1984 → Mar 26, 2010
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5733925A | Therapeutic inhibitor of vascular smooth muscle cells | Physics | 560 | Expired |
| US5981568A | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 436 | Expired |
| US6074659A | Therapeutic inhibitor of vascular smooth muscle cells | Physics | 304 | Expired |
| US5811447A | Therapeutic inhibitor of vascular smooth muscle cells | Physics | 278 | Expired |
| US6306421A | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 174 | Expired |
| US6663881B2 | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 148 | Expired |
| US6491938B2 | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 137 | Expired |
| US6720350B2 | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 137 | Expired |
| US6569441B2 | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 131 | Expired |
| US5217705A | Method of diagnosing blood clots using fibrin-binding proteins | Emerging Cross-Sectional Technologies | 94 | Expired |
| US5106951A | Antibody conjugates | Human Necessities | 85 | Expired |
| US6358989B1 | Therapeutic inhibitor of vascular smooth muscle cells | Emerging Cross-Sectional Technologies | 56 | Expired |
| US5976535A | Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore | Chemistry; Metallurgy | 46 | Expired |
| US5608060A | Biotinidase-resistant biotin-DOTA conjugates | Human Necessities | 43 | Expired |
| US5283342A | Biotinylated small molecules | Emerging Cross-Sectional Technologies | 42 | Expired |
| US4877868A | Radionuclide antibody coupling | Emerging Cross-Sectional Technologies | 35 | Expired |
| US6015897A | Biotinamido-n-methylglycyl-seryl-o-succinamido-benzyl dota | Chemistry; Metallurgy | 34 | Expired |
| US5985826A | Methods of using hepatic-directed compounds in pretargeting strategies | Human Necessities | 33 | Expired |
| US5886143A | Hepatic-directed compounds and reagents for preparation thereof | Human Necessities | 31 | Expired |
| US5171563A | Cleavable linkers for the reduction of non-target organ retention of immunoconjugates | Emerging Cross-Sectional Technologies | 29 | Expired |
| US6358710B1 | Humanized antibodies that bind to the antigen bound by antibody NR-LU-13 | Chemistry; Metallurgy | 28 | Expired |
| US5112953A | Radiolabeled proteins for diagnostic or therapeutic use | Human Necessities | 25 | Expired |
| US5175257A | Radiolabeled proteins for diagnostic or therapeutic use | Human Necessities | 25 | Expired |
| US5630996A | Two-step pretargeting methods using improved biotin-active agent conjugates | Human Necessities | 24 | Expired |
| US7144991B2 | Streptavidin expressed gene fusions and methods of use thereof | Chemistry; Metallurgy | 22 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.